Description

Microarray Panel:Lung cancer-metastasis-normal No. of samples59No. of patients40Core diameter2.0 mmFormat:Formalin FixedSection thickness 4 micrometer Core# No. Age Sex Organ Diagnosis pTNM Stage Months* Tissuetype Image 1 63 M Lung squamous cell carcinoma T2aN0M0 I B . 6 " class="fd_image"> 2 63 M Lung squamous cell carcinoma T2aN0M0 I B . 6 " class="fd_image"> 3 50 M Lung squamous cell carcinoma T2aN1M0 IIA . 6 " class="fd_image"> 4 67 M Lung squamous cell carcinoma T2aN1M0 IIA . 6 " class="fd_image"> 5 54 M Lung squamous cell carcinoma T2aN0M0 I B . 6 " class="fd_image"> 6 39 M Lung squamous cell carcinoma T4N1M0 IIIA . 6 " class="fd_image"> 7 71 M Lung squamous cell carcinoma T2bN0M0 IIA . 6 " class="fd_image"> 8 67 M Lung squamous cell carcinoma T2aN1M0 IIA . 6 " class="fd_image"> 9 65 M Lung squamous cell carcinoma T3N1M0 IIIA . 6 " class="fd_image"> 10 47 M Lung adenocarcinoma T2aN1M0 IIA . 6 " class="fd_image"> 11 38 M Lung adenocarcinoma T2bN0M0 IIA . 6 " class="fd_image"> 12 48 F Lung adenocarcinoma T1bN0M0 I A . 6 " class="fd_image"> 13 67 M Lung adenocarcinoma T2aN0M0 I B . 6 " class="fd_image"> 14 55 M Lung bronchioloalveolar carcinoma T1bN0M0 I A . 6 " class="fd_image"> 15 69 F Lung bronchioloalveolar carcinoma T2aN0M0 I B . 6 " class="fd_image"> 16 52 F Lung bronchioloalveolar carcinoma T2aN0M0 I B . 6 " class="fd_image"> 17 34 M Lung bronchioloalveolar carcinoma T2bN0M0 I B . 6 " class="fd_image"> 18 47 M Lung adenosquamous carcinoma T2aN2M0 IIIA . 6 " class="fd_image"> 19 60 M Lung adenosquamous carcinoma T2aN2M0 IIIA . 6 " class="fd_image"> 20 60 F Lung small cell carcinoma T2bN0M0 IIA . 6 " class="fd_image"> 21 65 M Lung small cell carcinoma T2aN0M0 I B . 6 " class="fd_image"> 22 60 M Lung combined small cell and adenocarcinoma T2bN1M0 IIB . 6 " class="fd_image"> 23 43 M Lung large cell carcinoma T2aN2M0 IIIA . 6 " class="fd_image"> 24 56 M Lung large cell carcinoma T2aN1M0 IIA . 6 " class="fd_image"> 25 63 M Lung large cell carcinoma T2bN0M0 IIA . 6 " class="fd_image"> 26 37 M Lung mucoepidermoid carcinoma T1aN0M0 I A . 6 " class="fd_image"> 27 40 F Lung mucoepidermoid carcinoma T2aN1M1b IV . 6 " class="fd_image"> 28 26 F Lung mucoepidermoid carcinoma T2aN0M0 I B . 6 " class="fd_image"> 29 54 F Lung adenoid cystic carcinoma T4N1M0 IIIA . 6 " class="fd_image"> 30 37 M Pleura malignant mesothelioma T2bN0M0 IIA . 6 " class="fd_image"> 31 45 M Lung squamous cell carcinoma T4N2M0 IIIB . 6 " class="fd_image"> 32 59 M Lung squamous cell carcinoma T4N2M0 IIIB . 6 " class="fd_image"> 33 62 M Lung squamous cell carcinoma T2aN2M0 IIIA . 6 " class="fd_image"> 34 39 M Lung squamous cell carcinoma T2aN1M0 IIA . 6 " class="fd_image"> 35 58 M Lung adenocarcinoma T2aN0M0 I B . 6 " class="fd_image"> 36 54 M Lung adenocarcinoma T2aN1M0 IIA . 6 " class="fd_image"> 37 62 F Lung adenocarcinoma T4N2M0 IIIB . 6 " class="fd_image"> 38 72 M Lung mucinous adenocarcinoma T2bN2M0 IIIA . 6 " class="fd_image"> 39 67 F Lung adenosquamous cell carcinoma T2aN2M0 IIIA . 6 " class="fd_image"> 40 56 M Lung mucoepidermoid carcinoma T2bN0M0 IIA . 6 " class="fd_image"> 41 45 M Lymph node metastatic carcinoma from #31 . . 0 6 " class="fd_image"> 42 59 M Lymph node metastatic carcinoma from #32 . . 0 6 " class="fd_image"> 43 62 M Lymph node metastatic carcinoma from #33 . . 0 6 " class="fd_image"> 44 39 M Lymph node matastatic carcinoma from #34 . . 0 6 " class="fd_image"> 45 66 M Bone metastatic carcinoma from #35 . . 17 6 " class="fd_image"> 46 54 M Lymph node metastatic carcinoma from #36 . . 0 6 " class="fd_image"> 47 62 F Lymph node metastatic carcinoma from #37 . . 0 6 " class="fd_image"> 48 72 M Lymph node metastatic carcinoma from #38 . . 0 6 " class="fd_image"> 49 76 F Bone, femur metastatic carcinoma from #39 . . 17 6 " class="fd_image"> 50 63 M Soft tissue metastatic carcinoma from #40 . . 11 6 " class="fd_image"> 51 67 M Lung normal lung (adjacent to cancer, match of #8) . . . 3 " class="fd_image"> 52 48 M Lung normal lung (adjacent to cancer, match of #12) . . . 3 " class="fd_image"> 53 34 M Lung normal lung (adjacent to cancer, match of #17) . . . 3 " class="fd_image"> 54 60 F Lung normal lung (adjacent to cancer, match of #20) . . . 3 " class="fd_image"> 55 59 M Lung normal lung (adjacent to cancer, match of #32) . . . 3 " class="fd_image"> 56 63 M Lung normal lung (apart from cancer, match of #1) . . . 3 " class="fd_image"> 57 55 M Lung normal lung (apart from cancer, match of #14) . . . 3 " class="fd_image"> 58 43 M Lung normal lung (apart from cancer, match of #23) . . . 3 " class="fd_image"> 59 58 M Lung normal lung (apart from cancer, match of #35) . . . 3 " class="fd_image"> 60 . . Carbon . . . . .

Application Notes	Use in Immunohistochemistryreported in scientific literature (PMID 28342003).
Publications	ReadPublications using NBP2-30222 in the following applications: IHC 1 publication IHC-P 3 publications

Novus Biologicals北京代理，Novus Biologicals中国代理，Novus Biologicals上海代理，Novus Biologicals公司，Novus Biologicals 【详细说明】  Novus Biologicals北京代理，Novus Biologicals中国代理，Novus Biologicals上海代理，Novus Biologicals公司，Novus Biologicals 上海普迈生物科技有限公司签约代理      欢迎下载下面的资料以了解此产品的相关信息！预询产品订购信息  上海普迈生物致力于提供zui高质量的产品和服务组织形态学研究与竞争力的产品 产品和服务,有相关产品的问题请直接 期货每周下午5点前发定单，正常到上海时间为3-4周 现市区2天内送到，外地以快递为准 敬请关注！ ：   :www.pumaibio.com :pumaibio :（直接客户） （经销商） 促销etonbio、polysciences、Mattek、trevigen、Chromogenix、cyguns、IrvineScientific、Innovative Cell Technologies、enzo、novus、immunochemistry、eylabs、Polyplus、NIBSC、ALZET、hitobiotec、sutter instrument、mirus、StressMarq、Avanti、jena bioscience、Neuro Probe、tedpella、avanti、Rockland、CAYMAN、transgenomic、BioLegend、ambion、omicronbio、 Assaybiotech、chondrex、lc?laboratories、cosmobio、megazyme、NeoMarkers、BTI、eylabs、berryassoc、cellagentech、TOCRIS、Relia Tech、SouthernBiotech、Biosearch technology、Lumiprobe、StemCells?Inc、biovendor、NORGEN、alomone、jena?bioscience、Gracebio、Eurogentec、Gelcompany?、invitrogen、gene?bridges、MRC-Holland、laysanbio